Department of Biological Sciences, University of Calgary, Calgary, Alberta T2N 1N4, Canada.
J Biomed Nanotechnol. 2010 Apr;6(2):145-52. doi: 10.1166/jbn.2010.1114.
Given the current interest in the pulmonary route for targeted drug delivery, assessing the impact of drug delivery vehicles on the surfactant layer lining the surface of the lung alveoli is critical. As gelatin-based nanoparticles are one such vehicle, this study addresses their interaction with the major saturated phospholipid component of native lung surfactant, dipalmitoylphosphatidylcholine (DPPC). Nanoparticles are colloidal particles in the size range of 1 to 1000 nm that are presently investigated for site-specific drug delivery in the emerging field of nanomedicine. Monolayer studies of DPPC films were performed both in the presence and absence of nanoparticles in order to assess the interaction in terms of average molecular areas occupied at given surface pressures. In Brewster angle microscopy experiments, nanoparticles significantly changed the shape and reduced the size of DPPC domains suggesting a considerable interaction of the two systems. For safe pulmonary drug delivery, understanding this interaction is a prerequisite so nanoparticles can be a feasible alternative to more conventional therapies in the future.
鉴于目前人们对通过肺部途径进行靶向药物输送的浓厚兴趣,评估药物输送载体对肺泡表面衬里的表面活性剂层的影响至关重要。由于基于明胶的纳米颗粒是这样的载体之一,因此本研究探讨了它们与天然肺表面活性剂的主要饱和磷脂成分二棕榈酰磷脂酰胆碱(DPPC)的相互作用。纳米颗粒是胶体颗粒,其尺寸范围在 1 至 1000nm 之间,目前正在新兴的纳米医学领域中研究用于特定部位的药物输送。为了根据在给定表面压力下占据的平均分子面积来评估相互作用,在存在和不存在纳米颗粒的情况下进行了 DPPC 膜的单层研究。在布鲁斯特角显微镜实验中,纳米颗粒明显改变了 DPPC 区域的形状并减小了其尺寸,这表明两个系统之间存在相当大的相互作用。为了进行安全的肺部药物输送,了解这种相互作用是前提条件,因此纳米颗粒将来可能成为更传统疗法的可行替代方法。